Diligence memo · auto-generated · as of July 3, 2026
InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc. looks over-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
InMed Pharmaceuticals Inc. operates in Pharmaceuticals, based in VANCOUVER.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
InMed Pharmaceuticals Inc. has raised $29M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $12M on 2021-07-02.
Most recent recorded round closed around 2022-11-21.
Valuation (modeled)modeled
Provath models InMed Pharmaceuticals Inc. at approximately $64M (range $6.9M–$200M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.95× the median modeled value of Series A Pharmaceuticals companies in 2022–2024 (64 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 15 months.
Last raise 3.6 yr ago; this sector typically re-raises about every 13 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round stepped up 1.2× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 73% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 47% of those peers.
Closest niche peers: Hallux, Inc., Enalare Therapeutics Inc., Silver Creek Pharmaceuticals, Inc., NQ PE Project Stingray Parent, L.P., Acta Pharmaceuticals, Inc..
Peoplefiled
20 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.